ZIOPHARM Oncology, Inc. Announces Unanimous Recombinant DNA Advisory Committee (RAC) Approval For Phase 1 Study Of Ad-RTS-IL-12 In Subjects With Recurrent Or Progressive Glioblastoma

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON, Dec. 6, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced the unanimous approval of the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) for the initiation of a Phase 1 study of Ad-RTS-IL-12, an adenoviral vector engineered to express interleukin-12 under the control of veledimex, an oral activator, in subjects with recurrent or progressive glioblastoma or grade III malignant glioma (brain cancer). ZIOPHARM has announced plans to launch a Phase 1 study of Ad-RTS-IL-12 in malignant glioma in the first half of 2014. The Company is currently studying Ad-RTS-IL-12 in Phase 2 studies in melanoma and breast cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news